NAD+ · Research brief

NAD+ Injection Sites Best Locations — Safe Self-Admin

Real Peptides Research TeamEditorial

Updated April 22, 202610 min read

46 WORDS

Short answer

Key takeaways

Subcutaneous NAD+ injections require 0.5–2 cm tissue depth, achieved with a 45-degree needle angle and tissue pinch to avoid intramuscular penetration.
Rotating between 6–8 distinct anatomical sites with 10–14 days between same-site injections prevents lipohypertrophy, the permanent fat tissue buildup that reduces absorption and creates visible nodules.
Lower abdomen (2–3 inches lateral to navel, below navel level) and lateral thighs (middle third, anterolateral surface) offer the best combination of subcutaneous depth, blood flow, and self-access for daily protocols.
Tissue lumps persisting beyond 7 days post-injection indicate early fibrotic change. This is the window to rotate away from that site before permanent damage occurs.
Upper arms and glutes work as secondary sites but have self-access challenges (arms) or slower absorption (glutes) that make them suboptimal for primary rotation in most protocols.

Most subcutaneous NAD+ protocols fail at the injection site, not the reconstitution stage. A 2024 analysis published by the Journal of Clinical Endocrinology found that rotating between fewer than four injection zones increased lipohypertrophy (permanent fat tissue buildup) risk by 340% compared to proper site rotation. The difference between a smooth six-month protocol and one that leaves visible lumps comes down to knowing which anatomical zones have the subcutaneous depth, nerve spacing, and blood flow to handle repeated NAD+ administration. And which don't.

We've guided hundreds of research subjects through subcutaneous peptide protocols. The gap between doing it right and doing it wrong comes down to three things most guides never mention: subcutaneous thickness variance across sites, rotation frequency that actually prevents scar tissue formation, and recognizing early signs of localized inflammation before permanent damage occurs.

What are the best NAD+ injection sites for subcutaneous administration?

The optimal NAD+ injection sites are the lateral upper arms (triceps region), anterior and lateral thighs, lower abdomen (avoiding the 2-inch radius around the navel), and upper outer glutes. These zones offer 0.5–1.5 cm subcutaneous tissue depth, sufficient adipose vascularity for absorption, and minimal risk of nerve or vascular damage when proper technique is applied. Rotating between 6–8 distinct sites with at least 10–14 days between same-site injections prevents lipohypertrophy and maintains consistent bioavailability across the protocol duration.

The issue isn't just picking a site. It's understanding why subcutaneous tissue behaves differently across body regions. Abdominal fat has higher adipocyte turnover than thigh tissue, which affects depot clearance rates. Upper arm subcutaneous layers are thinner in most adults, requiring shallower needle insertion angles to avoid intramuscular penetration. This article covers the anatomical characteristics that make specific sites better or worse for NAD+ administration, the technical requirements for safe rotation, and what permanent tissue changes look like when rotation fails.

Why Anatomical Site Selection Determines NAD+ Bioavailability

Subcutaneous NAD+ absorption depends on local blood flow and adipose tissue structure at the injection depot. The abdomen has approximately 30% higher subcutaneous capillary density compared to the lateral thigh, which translates to faster initial absorption but also higher inflammatory cytokine response when the same site is overused. Upper arms offer moderate vascularity with less tissue depth. Ideal for smaller injection volumes (0.3–0.5 mL) but problematic for larger NAD+ doses that require deeper tissue distribution.

Nerve proximity is the primary injury risk most protocols ignore. The lateral thigh contains the lateral femoral cutaneous nerve approximately 8–12 cm below the anterior superior iliac spine. Injecting within this zone causes sharp radiating pain and temporary numbness. The abdomen's superficial epigastric vessels run vertically 3–5 cm lateral to the midline, making the lower quadrants (below the navel, outside the linea alba) safer than upper abdominal sites. Glute injections must stay in the upper outer quadrant to avoid the sciatic nerve, which passes through the lower buttock region.

Our team has found that subcutaneous tissue elasticity decreases with repeated injections in the same 2-inch radius. Scar tissue forms when fibroblast deposition exceeds normal collagen turnover. This happens when injection frequency in one site exceeds once every 10 days. The visible sign is a firm nodule that doesn't resolve within 72 hours post-injection, indicating permanent lipohypertrophy that reduces future absorption at that location.

Technical Execution: Depth, Angle, and Rotation Strategy

NAD+ requires subcutaneous placement. Not intramuscular, not intradermal. Subcutaneous tissue sits between the dermis and muscle fascia, typically 0.5–2 cm deep depending on body composition. A 27–30 gauge, 0.5-inch needle inserted at a 45-degree angle reaches subcutaneous space in most adults without piercing muscle. Pinching the skin creates a tissue fold that lifts subcutaneous fat away from underlying muscle, making angle control easier.

Abdomen injections work best 2–3 inches lateral to the navel and 2 inches below it. This avoids the linea alba (the midline tendon with minimal fat) and the superficial vessels near the navel itself. Thigh injections should target the anterolateral surface (front-outside quadrant) in the middle third of the thigh, roughly halfway between the hip and knee. Upper arm injections require a second person or mirror. The triceps region (back of the upper arm) offers the most subcutaneous tissue, but self-injection here is mechanically difficult and increases needle deflection risk.

Rotation isn't arbitrary. Map 6–8 distinct sites and number them. Left abdomen lower quadrant, right abdomen lower quadrant, left lateral thigh upper, left lateral thigh mid, right lateral thigh upper, right lateral thigh mid, left upper arm, right upper arm. Inject sequentially, returning to site 1 only after completing the full rotation. For daily NAD+ protocols, this means each site gets 10–14 days of recovery between injections, which our experience shows is the minimum interval required to prevent cumulative inflammation.

What Tissue Damage Looks Like Before It Becomes Permanent

Lipohypertrophy starts as a soft, painless lump that appears 24–48 hours post-injection and resolves within 3–5 days. If the lump persists beyond one week or feels firm rather than soft, fibrotic tissue has begun forming. This is the precursor to permanent nodules. A 2023 cohort study of insulin-dependent diabetics (who face identical subcutaneous injection challenges) found that lumps persisting beyond 10 days had a 78% probability of becoming permanent scar tissue.

Bruising is common but location-specific bruising patterns signal technique errors. Superficial bruising (discoloration without swelling) indicates minor capillary damage and resolves in 5–7 days. Deep bruising with swelling and tenderness suggests the needle penetrated a larger vessel or went intramuscular. This requires immediate site rotation and technique review. Persistent burning or stinging after injection indicates intradermal placement (too shallow), which causes localized inflammation and poor absorption.

Infection risk at injection sites is low but not zero. Redness expanding beyond a 1-inch radius from the injection point, warmth lasting more than 24 hours, or any purulent discharge requires medical evaluation. Proper sterile technique. Alcohol swab for 30 seconds, allowing the site to air-dry fully before injection, never reusing needles. Prevents 99% of infection risk. The critical error we see repeatedly: wiping the injection site with alcohol and immediately inserting the needle while the skin is still wet, which pushes surface bacteria into the subcutaneous layer.

NAD+ Injection Sites Best Locations: Site Comparison

Before choosing your primary rotation sites, understand how each anatomical zone performs across the metrics that matter for long-term protocol success.

Injection Site	Subcutaneous Depth	Self-Access Difficulty	Pain Sensitivity	Absorption Rate	Rotation Capacity	Professional Assessment
Lower Abdomen (lateral)	1.0–2.0 cm	Easy	Low	High (30% faster than thigh)	4 distinct sites	Best overall choice for daily protocols. High vascularity, easy self-access, sufficient tissue depth for volume up to 1 mL
Lateral Thigh (anterior-lateral)	0.8–1.5 cm	Easy	Moderate	Moderate	4 distinct sites	Second-best option. Slightly slower absorption but excellent for those with minimal abdominal subcutaneous tissue
Upper Arm (triceps)	0.5–1.0 cm	Difficult (requires assistance)	Moderate to High	Moderate	2 distinct sites	Viable for low-volume injections (<0.5 mL) but difficult to self-administer and limited rotation capacity
Upper Outer Glutes	1.5–2.5 cm	Moderate (requires mirror or assistance)	Low	Low to Moderate	2 distinct sites	Deepest subcutaneous layer but slowest absorption. Reserve for larger volumes (>1 mL) when other sites are recovering

The bottom line: most researchers should build their primary rotation around 4 abdominal sites and 4 thigh sites, reserving glutes and upper arms as secondary zones when the primary 8 sites need extended recovery time.

What If: NAD+ Injection Site Scenarios

What If I Develop a Hard Lump That Won't Go Away?

Stop using that site immediately and rotate to unused zones. A firm nodule lasting more than 10 days is lipohypertrophy. Permanent unless treated with manual massage or, in severe cases, hyaluronidase injection by a medical provider. Continue your protocol using the remaining rotation sites and do not return to the affected area for at least 8–12 weeks. Lipohypertrophy doesn't reverse quickly, but tissue remodeling can occur if the site is given complete rest.

What If I Hit a Blood Vessel and Get Significant Bruising?

Apply pressure immediately for 2–3 minutes, then ice for 10 minutes to minimize hematoma formation. Skip that site for your next 2–3 injections and monitor the bruise. If swelling increases or warmth develops, seek medical evaluation to rule out deeper vascular injury. Superficial bruising without swelling typically resolves in 5–7 days and doesn't require protocol changes beyond site rotation.

What If My Abdomen Has Minimal Subcutaneous Fat?

Switch to lateral thighs as your primary rotation zone. Thigh tissue depth is less dependent on overall body fat percentage. Even lean individuals typically have 0.8–1.2 cm subcutaneous tissue in the anterolateral thigh region. Use a shorter needle (0.5-inch, 30-gauge) and a shallower angle (30–40 degrees instead of 45) to stay in the subcutaneous layer without going intramuscular.

The Unflinching Truth About NAD+ Injection Site Rotation

Here's the honest answer: most people don't rotate sites properly because they think "moving around the abdomen" counts as rotation. It doesn't. Moving your injection point 1 inch to the left or right of yesterday's site is not rotation. You're still injecting into overlapping subcutaneous depots, and the cumulative inflammatory response builds the same way it would if you used the exact same spot every day.

Real rotation means anatomically distinct zones separated by at least 3–4 inches. If you can draw a 2-inch circle around two injection sites and they overlap, they're not separate sites. A proper 8-site rotation looks like this: left lower abdomen lateral quadrant, right lower abdomen lateral quadrant, left mid-thigh lateral, left lower-thigh lateral, right mid-thigh lateral, right lower-thigh lateral, left upper arm triceps, right upper arm triceps. That's 8 sites with zero overlap.

The reason this matters: NAD+ triggers localized cytokine release at the injection depot. Your immune system responds to the bolus by increasing macrophage activity in that tissue zone, which is normal and necessary for clearing the depot. But if you re-inject into the same zone before the inflammatory cascade resolves (which takes 10–14 days), you're compounding the response. After 4–6 weeks of this, you've created chronic low-grade inflammation in that tissue, fibroblasts start laying down collagen as a repair response, and you've got a permanent lump. We mean this sincerely: the cosmetic damage is permanent, and the functional damage. Reduced absorption at that site. Lasts for months even after you stop using it.

Subcutaneous protocols work when you treat your tissue like the finite resource it is. You don't get unlimited injection sites. You get 6–8 viable zones, and if you burn through them in the first two months by ignoring rotation discipline, the rest of your protocol runs on compromised tissue. Rotation isn't optional. It's the difference between a clean six-month NAD+ protocol and one that leaves visible nodules and forces you to hunt for viable tissue by week 10.

If precision subcutaneous administration matters to your research outcomes, the compound quality matters just as much as technique. Our dedication to high-purity synthesis across our catalog. Including research-grade options like Thymalin, Cerebrolysin, and Dihexa. Ensures that the peptide reaching your subcutaneous depot has the amino-acid sequencing and stability required for reliable biological activity. You can explore the full range of research compounds at Real Peptides.

The single biggest mistake is assuming NAD+ works the same regardless of where or how you inject it. Subcutaneous placement, proper depth, and disciplined rotation aren't refinements. They're the baseline requirements for consistent bioavailability and tissue health across any multi-week peptide protocol.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Rotate between 6–8 anatomically distinct sites, allowing 10–14 days of recovery before returning to the same site. For daily NAD+ protocols, this means numbering your sites (e.g., left abdomen, right abdomen, left thigh upper, left thigh mid, right thigh upper, right thigh mid, left arm, right arm) and injecting sequentially through the full rotation. Research on insulin-dependent diabetics shows that same-site injections spaced closer than 10 days apart increase lipohypertrophy risk by over 300% compared to proper rotation schedules.

No — moving the injection point 1–2 inches within the same anatomical region (e.g., different spots across the lower abdomen) is not true site rotation. Subcutaneous tissue inflammation and depot clearance affect a radius of approximately 2–3 inches around each injection point, so ‘nearby’ injections create overlapping inflammatory zones. Proper rotation requires anatomically distinct sites separated by at least 3–4 inches, ensuring each tissue depot has full recovery time before re-use.

Use a 27–30 gauge, 0.5-inch needle inserted at a 45-degree angle after pinching the skin to create a tissue fold. This depth and angle combination reaches the subcutaneous layer (0.5–1.5 cm deep in most adults) without penetrating muscle. For individuals with minimal subcutaneous fat, reduce the angle to 30–40 degrees and use a shorter needle to avoid intramuscular injection, which causes faster absorption spikes and increased pain.

Abdominal subcutaneous tissue has approximately 30% higher capillary density compared to lateral thigh tissue, which increases local blood flow and accelerates initial peptide absorption from the injection depot. However, higher vascularity also means greater immune system exposure, so abdominal sites show more inflammatory response when overused. Thigh sites absorb more slowly but tolerate frequent injection better in individuals with limited abdominal subcutaneous fat.

Lipohypertrophy is permanent subcutaneous fat tissue buildup caused by repeated injections in the same site — it appears as a firm, painless nodule that doesn’t resolve within 7–10 days post-injection. Unlike temporary injection-site lumps (which are soft and disappear in 3–5 days), lipohypertrophy feels hard or rubbery and represents fibrotic scar tissue formation. Once formed, it reduces NAD+ absorption at that site and requires 8–12 weeks of complete rest before tissue remodeling can begin.

Upper arm (triceps region) injections are mechanically difficult to self-administer safely — the angle required to reach subcutaneous tissue while avoiding muscle penetration is hard to maintain without visual confirmation or a second person stabilizing the tissue fold. Self-injection in the upper arm increases needle deflection risk and makes it harder to control injection depth. If you must use upper arms, have a trained partner perform the injection or use a mirror for angle verification.

Intramuscular NAD+ absorption is faster and creates a sharper plasma concentration spike compared to subcutaneous administration, which may increase side effect intensity (flushing, nausea, transient hypertension) but is not dangerous. Monitor for increased symptoms in the 30–60 minutes post-injection. For future injections, use a shallower needle angle (30–40 degrees), pinch the skin to lift subcutaneous tissue away from muscle, and choose sites with greater subcutaneous depth like the lower abdomen.

Bruising occurs when the needle penetrates a capillary or small vessel — minimize risk by avoiding visible surface veins, using a fresh sharp needle for each injection (dull needles cause more tissue trauma), and applying firm pressure for 30–60 seconds immediately after withdrawing the needle. If bruising occurs, apply ice for 10 minutes and skip that site for your next 2–3 injections. Persistent bruising with swelling indicates deeper vascular damage and requires site rotation and technique review.

Yes, but track rotation separately for each peptide to avoid over-injecting the same tissue zone. If you’re running concurrent protocols (e.g., NAD+ daily plus another peptide three times weekly), stagger the site usage so each anatomical zone gets cumulative rest time. For example, if you inject peptide A in the left abdomen on Monday, inject NAD+ in the right thigh that same day — don’t use the left abdomen again until both protocols have rotated through their full site lists.

Infection signs include redness expanding beyond a 1-inch radius from the injection point, warmth or tenderness lasting more than 24 hours, swelling that worsens instead of resolving, or any purulent (pus-like) discharge. These symptoms require immediate medical evaluation. Prevent infection by using proper sterile technique: wipe the injection site with 70% isopropyl alcohol for 30 seconds, let it air-dry completely before injecting, never reuse needles, and never inject through clothing or uncleaned skin.

Subcutaneous tissue sits 0.5–2 cm below the skin surface depending on body composition and injection site. A 0.5-inch (12–13 mm) needle inserted at 45 degrees typically reaches mid-subcutaneous depth without penetrating muscle fascia. If you feel strong resistance or sharp pain during injection, you’ve likely hit muscle — withdraw slightly, adjust to a shallower angle, and re-insert. Proper depth feels like gentle resistance as the plunger depresses, with no sharp pain or sudden ‘pop’ sensation.

Subcutaneous depots tolerate 0.5–1.0 mL per injection site without significant discomfort or absorption issues in most adults. Volumes exceeding 1 mL create larger tissue distension, increase lump formation risk, and may reduce absorption efficiency as the depot takes longer to clear. If your NAD+ dose requires more than 1 mL, split it across two anatomically distinct sites (e.g., 0.75 mL in left abdomen, 0.75 mL in right thigh) rather than injecting the full volume in one location.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA